Epithelial–mesenchymal transition (EMT) is an essential process in normal embryonic
development and tissue regeneration. However, aberrant reactivation of EMT is associated …

Epithelial–mesenchymal transition (EMT) has been shown to play a critical role in tumor
development from initiation to metastasis. EMT could be regarded as a continuum, with …

Therapeutic checkpoint antibodies blocking programmed death receptor 1/programmed
death ligand 1 (PD-L1) signaling have radically improved clinical outcomes in cancer …

Epithelial–mesenchymal transition (EMT) is a crucial embryonic programme that is executed
by various EMT transcription factors (EMT-TFs) and is aberrantly activated in cancer and …

Resistance to cancer therapy is a major barrier to cancer management. Conventional views
have proposed that acquisition of resistance may result from genetic mutations. However …

Antibodies targeting immune checkpoints are emerging as potent and viable cancer
therapies, but not all patients respond to these as single agents. Concurrently targeting …

Immune checkpoint blockage has been considered a breakthrough in cancer treatment,
achieving encouraging anti-tumor effects in some advanced solid malignancies. However …

Evasion of immune system is a hallmark of cancer, which enables cancer cells to escape the
attack from immune cells. Cancer cells can express many immune inhibitory signalling …

Metastatic spread of tumour cells is the main cause of cancer-related deaths. Understanding
the mechanisms of tumour-cell dissemination has, therefore, become an important focus for …

Programmed death-ligand 1 (PD-L1) is an immune checkpoint inhibitor that binds to its
receptor PD-1 expressed by T cells and other immune cells to regulate immune responses; …